EG 016

Drug Profile

EG 016

Alternative Names: Ad-VEGF-A; EG016

Latest Information Update: 23 Nov 2012

Price : $50

At a glance

  • Originator Ark Therapeutics
  • Class Gene therapies
  • Mechanism of Action Gene transference; Vascular endothelial growth factor D stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Peripheral vascular disorders

Most Recent Events

  • 08 Nov 2012 Discontinued - Phase-I/II for Peripheral vascular disorders in Finland (IM)
  • 16 Mar 2011 Phase-I/II development is ongoing in Finland
  • 19 Apr 2010 Phase-I/II clinical trials in Peripheral vascular disorders in Finland (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top